Input | Output | |||||||
---|---|---|---|---|---|---|---|---|
Study Site | Age of SP IPTi administration (months) | Mean incidence in placebo group (episodes per person year) (λ (a)/2) | ITN coverage (%) | Estimated*** cross sectional prevalence parasitaemia at start of study (%) | Estimated Day 28 ACPR for SP ( σ × 100) | Model estimate of PE (%) | Actual PE of IPTi (% 95% CI) | Ratio model:study |
Ifakara | 2,3 and 9 | 0.54 | 67 | 4.5 | 60 | 23.0 | 58.8 (40.8–71.3) | 0.39 |
Navrongo | 2,4,9 and 12 | 1 | 18 | 8.3 | 65* | 31.9 | 29.3 (17.7–39.5) | 1.09 |
Mahnica | 3,4 and 9 | 0.71 | 0 | 5.9 | 65* | 32.0 | 20.1 (2.1–34.9) | 1.59 |
Kumasi | 3,9 and 15 | 1.27 | 20 | 10.6 | 69** | 25.9 | 20.9 (8.9–31.3) | 1.24 |
Tamale | 3,9 and 15 | 0.93 | 1 | 7.8 | 69 | 24.9 | 33.3 (20.7–43.8) | 0.75 |
Lamberene | 3,9 and 15 | 0.16 | 5 | 1.3 | 65* | 23.7 | 22.0 (-25.4–51.5) | 1.08 |